X4 Pharmaceuticals, Inc.
XFOR
$0.21
-$0.0016-0.76%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 73.27% | 75.17% | 62.30% | 71.82% | 31.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.89% | 22.34% | 23.13% | 20.82% | 22.08% |
| Operating Income | -31.51% | -21.30% | -22.57% | -20.82% | -22.08% |
| Income Before Tax | 63.26% | 84.99% | 113.59% | -34.31% | -7.73% |
| Income Tax Expenses | 297.44% | 44.07% | 380.00% | 933.33% | 178.57% |
| Earnings from Continuing Operations | 62.98% | 84.92% | 113.52% | -34.39% | -7.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 62.98% | 84.92% | 113.52% | -34.39% | -7.78% |
| EBIT | -31.51% | -21.30% | -22.57% | -20.82% | -22.08% |
| EBITDA | -31.28% | -21.30% | -22.76% | -21.09% | -22.31% |
| EPS Basic | 69.39% | 89.38% | 108.27% | 47.00% | 67.74% |
| Normalized Basic EPS | -17.38% | 23.52% | 58.11% | 46.89% | 66.77% |
| EPS Diluted | 68.88% | 88.92% | 107.92% | 46.97% | 67.72% |
| Normalized Diluted EPS | -17.35% | 23.54% | 58.12% | 46.89% | 66.77% |
| Average Basic Shares Outstanding | 13.20% | 30.63% | 59.66% | 109.23% | 180.65% |
| Average Diluted Shares Outstanding | 13.25% | 30.69% | 59.73% | 109.23% | 180.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
